JP2024522234A5 - - Google Patents

Info

Publication number
JP2024522234A5
JP2024522234A5 JP2023577758A JP2023577758A JP2024522234A5 JP 2024522234 A5 JP2024522234 A5 JP 2024522234A5 JP 2023577758 A JP2023577758 A JP 2023577758A JP 2023577758 A JP2023577758 A JP 2023577758A JP 2024522234 A5 JP2024522234 A5 JP 2024522234A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522234A (ja
Filing date
Publication date
Priority claimed from GBGB2108712.7A external-priority patent/GB202108712D0/en
Priority claimed from GBGB2115119.6A external-priority patent/GB202115119D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/066566 external-priority patent/WO2022263632A1/en
Publication of JP2024522234A publication Critical patent/JP2024522234A/ja
Publication of JP2024522234A5 publication Critical patent/JP2024522234A5/ja
Pending legal-status Critical Current

Links

JP2023577758A 2021-06-18 2022-06-17 新規な併用療法及びその使用 Pending JP2024522234A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2108712.7A GB202108712D0 (en) 2021-06-18 2021-06-18 Novel combination therapies and uses thereof
GB2108712.7 2021-06-18
GB2115119.6 2021-10-21
GBGB2115119.6A GB202115119D0 (en) 2021-10-21 2021-10-21 Novel combination therapies and uses thereof
PCT/EP2022/066566 WO2022263632A1 (en) 2021-06-18 2022-06-17 Novel combination therapies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024522234A JP2024522234A (ja) 2024-06-11
JP2024522234A5 true JP2024522234A5 (https=) 2025-06-25

Family

ID=82321438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577758A Pending JP2024522234A (ja) 2021-06-18 2022-06-17 新規な併用療法及びその使用

Country Status (4)

Country Link
US (1) US20240287199A1 (https=)
EP (1) EP4355780A1 (https=)
JP (1) JP2024522234A (https=)
WO (1) WO2022263632A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120446488B (zh) * 2025-07-08 2025-09-12 杭州华得森生物技术有限公司 用于多重免疫检测的试剂盒及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
US10899840B2 (en) * 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
KR20250004095A (ko) * 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
WO2020239558A1 (en) * 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors

Similar Documents

Publication Publication Date Title
JP2022101693A5 (https=)
JP2020501531A5 (https=)
RU2019116624A (ru) Новые анти_cd137 антитела и их применение
JP2023509323A5 (https=)
JP2022516505A (ja) 癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
JP2021501162A5 (https=)
CN110799543A (zh) 肝细胞癌的免疫治疗
JP2023089245A5 (https=)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2018503365A5 (https=)
JP2023549537A5 (https=)
JP2021520201A5 (https=)
JP2024016024A5 (https=)
JP2022512642A5 (https=)
JP2020528936A5 (https=)
JP2023037000A5 (https=)
JP2022553922A5 (https=)
JP2022553851A5 (https=)
JP2024001073A5 (https=)
CN112351794A (zh) 用于尿路上皮癌的免疫治疗方法
JP2023545521A5 (https=)
CN113574069A (zh) 抗pd-l1抗体及其用途
JP2024535930A5 (https=)
JP2023517754A5 (https=)
JP2023509215A5 (https=)